Oluwadamilare Shoneye
Psychiatric/Mental Health · New Castle, DENPI 1659009231
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $888, 3.5 times the $254 reported in 2022.
Across 134 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$343
- Supernus Pharmaceuticals, Inc.$306
- Alkermes, Inc.$272
- Johnson & Johnson$269
- Vanda Pharmaceuticals Inc.$253
- Otsuka America Pharmaceutical, Inc.$236
- plus $876 from 12 others
What the payments were for
- Food & beverage$2,51798%
- Education$392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 18 | $343 |
| Supernus Pharmaceuticals, Inc. | 20 | $306 |
| Alkermes, Inc. | 13 | $272 |
| Johnson & Johnson | 15 | $269 |
| Vanda Pharmaceuticals Inc. | 12 | $253 |
| Otsuka America Pharmaceutical, Inc. | 13 | $236 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $198 |
| Neurocrine Biosciences, Inc. | 6 | $134 |
| Teva Pharmaceuticals USA, Inc. | 6 | $114 |
| Lundbeck LLC | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 3 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Indivior Inc. | 3 | $57 |
| Braeburn Inc. | 2 | $40 |
| Noven Therapeutics, LLC | 2 | $35 |
| Almatica Pharma LLC | 2 | $33 |
| Tris Pharma Inc | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
How this compares
$2,556 in reported general payments places this provider in the 80th percentile of 177 psychiatric/mental health providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LybalviOlanzapine/Samidorphan Malate | 12 | $18,922 |
| RexultiBrexpiprazole | 11 | $13,450 |
| Lurasidone Hcl | 12 | $5,111 |
| Duloxetine Hcl | 35 | $2,464 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 34 | $1,245 |
| Trazodone Hcl | 12 | $957 |
| Alprazolam ErAlprazolam | 14 | $940 |
| Temazepam | 26 | $734 |
| Alprazolam | 61 | $441 |
| Memantine Hcl ErMemantine Hcl | 11 | $433 |
| Lamotrigine | 19 | $304 |
| Buspirone Hcl | 29 | $298 |
| Bupropion Hcl SrBupropion Hcl | 44 | $222 |
| Gabapentin | 31 | $192 |
| Mirtazapine | 26 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Lybalvi | $272 | $18,92212 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $236 | $13,45011 claims |
| Almatica Pharma LLCSertraline Hcl | $33 | $6212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 psychiatric/mental health providers in Delaware.
Other psychiatric/mental health in New Castle
- Michael KolodgieNew Castle$3K
- Guirlene ClervoixNew Castle$3K
- Cheryl GrantNew Castle$2K
- Tracee SherlockNew Castle$2K
- Ronald TyreeWilmington$59K
- Ericka Taylor-DanielDover$39K
- Cindy CunninghamDover$14K
- Kameka HartNewark$10K
- Jenika MilesWilmington$8K
- Catherine DotyNewport$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.